Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597058 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
A Phase 2 study of Alzheimer Disease, sponsored by Noah Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 16
- Study locations
NCT06597058 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Noah Pharmaceuticals. The registered enrollment target is 103 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 8 states.
The verdict
NCT06597058, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Noah Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 months from Screening of the first patient until the last follow-up of the last patients.
Conditions Studied
Interventions
- DRUG MAR
Study Locations (16)
Florida
- Accel Research Sites (Noah Clinical Site 019) - DeLand
- Health Awareness (Noah Clinical Site 020) - Jupiter
- Life Well Research Center (Noah Clinical Site 008) - Miami
- Regenerate Primary Medical Research (Noah Clinical Site 003) - Miami
- Miami Jewish Health (Noah Clinical Site 023) - Miami
- Neurology Associates of Ormond Beach (Noah Clinical Site 015) - Ormond Beach
- International Medical Investigational Centers (Noah Clinical Site 001) - Palmetto Bay
- Best Choice Medical and Research Service (Noah Clinical Site 025) - Pembroke Pines
- Denali Health Plant City, LLC (Noah Clinical Site 024) - Plant City
Arizona
- Scottsdale Clinical Trials (Noah Clinical Site 017) - Scottsdale
California
- Marvel Clinical Research (Noah Clinical Site 010) - Huntington Beach
Massachusetts
- Boston Clinical Trials (Noah Clinical Site 006) - Boston
New Mexico
- IMA Clinical Research (Noah Clinical Site 004) - Albuquerque
North Carolina
- Carolina Research Center, Inc. (Noah Clinical Site 009) - Shelby
Oklahoma
- Tekton Research (Noah Clinical Site 002) - Yukon
Texas
- Olympus Clinical Research (Noah Clinical Site 014) - Katy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2026-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06597058
The ClinicalTrials.gov registry entry for NCT06597058 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (96% lower). The listed sponsor is Noah Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which MAR is the first listed.
NCT06597058 reports 16 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06597058 about?
NCT06597058 is a clinical study titled "Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill". This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period. The anticipated study population are males and females aged 50-85 years with very mild to severe Alzhei...
What is the current status of trial NCT06597058?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2024-10-16. Estimated completion is 2026-02-15.
What conditions does trial NCT06597058 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06597058?
The interventions under investigation include: MAR (DRUG).
Who is sponsoring clinical trial NCT06597058?
This trial is sponsored by Noah Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597058 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Massachusetts, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.